Welcome to our dedicated page for Biodexa Pharmaceuticals plc SEC filings (Ticker: BDRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Biodexa Pharmaceuticals plc filings document a foreign private issuer that reports current information on Form 6-K and incorporates certain disclosures into Form S-8 and Form F-3 registration statements. The records cover preliminary annual results; pipeline disclosures for eRapa, MTX240 and tolimidone; clinical trial authorizations and enrollment updates; and material agreements such as the MTX240 license and collaboration arrangement.
Capital-structure disclosures describe ADS units, pre-funded warrants, Series L warrants, public-offering documents, ADR ratio matters and the relationship between ADSs and ordinary shares. Governance and corporate filings also cover executive and board appointments, exhibit-based press releases, and other foreign-issuer current reports tied to Biodexa’s biopharmaceutical development programs.
Biodexa Pharmaceuticals filed a prospectus supplement covering the resale by existing shareholders of up to 109,800,000 ordinary shares represented by 1,098 American Depositary Shares. The company also commenced a best efforts public offering of 157,000 ADS units and 2,891,781 pre-funded units, each unit including one ADS or pre-funded warrant plus two Series L warrants, at combined prices of $3.28 and $3.2799 per unit. Net proceeds from this offering are expected to be approximately $8.75 million to fund development programs, working capital and other general corporate purposes, with closing anticipated on or about December 19, 2025. As of September 30, 2025, cash and cash equivalents were £2.79 million, and after the offering the company expects to have 83,878,708,922 ordinary shares outstanding, assuming no warrant exercises.
Biodexa Pharmaceuticals PLC files a prospectus supplement covering the resale of up to 171,700,000 ordinary shares, represented by 1,717 American Depositary Shares (ADSs). Alongside this, the company has launched a best-efforts public offering of 157,000 ADS units and 2,891,781 pre-funded units, each unit including warrants. The offering is expected to generate approximately $8.75 million in net proceeds, which the company plans to use to fund its development programs, working capital and general corporate purposes. As of September 30, 2025, Biodexa reported cash and cash equivalents of £2.79 million, and assuming the offering closes with no warrant exercises, it will have 83,878,708,922 ordinary shares outstanding.
Biodexa Pharmaceuticals PLC supplements its resale prospectus covering up to 4,349,000,000 ordinary shares, represented by 43,490 American Depositary Shares (ADSs), that may be sold from time to time by existing shareholders. Alongside this, the company has begun a best efforts public offering of 157,000 ADS units, each with one ADS and two Series L warrants, and 2,891,781 pre-funded units, each with a pre-funded warrant and two Series L warrants, at combined prices of $3.28 and $3.2799 per unit, respectively.
The offering is expected to generate approximately $8.75 million in net proceeds, which the company plans to use for development programs, working capital and general corporate purposes. As of September 30, 2025, Biodexa reported cash and cash equivalents of £2.79 million83,878,708,922 ordinary shares outstanding. New Series L and pre-funded warrants carry exercise caps at 4.99% or 9.99% beneficial ownership to limit concentration.
Biodexa Pharmaceuticals is registering for resale up to 2,846,100,000 ordinary shares, represented by 24,861 American Depositary Shares (ADSs), held by existing shareholders. Separately, the company has begun a best efforts public offering of 157,000 ADS units and 2,891,781 pre-funded units, each unit including ADSs or pre-funded warrants plus two Series L warrants. Unit pricing is $3.28 per ADS unit and $3.2799 per pre-funded unit, with Series L warrants exercisable at $3.28 for five years and pre-funded warrants at $0.0001 per ADS. Net proceeds from this primary offering are expected to be about $8.75 million, intended for development programs, working capital and general corporate purposes. As of September 30, 2025, the company reported £2.79 million in cash and cash equivalents and later settled a previously disclosed advisor fee dispute via a payment. Assuming the offering closes and no warrants are exercised, 83,878,708,922 ordinary shares will be outstanding.
Biodexa Pharmaceuticals PLC has launched a best efforts public offering of 157,000 ADS Units and 2,891,781 Pre-Funded Units, each unit combining one ADS or pre-funded warrant with two Series L warrants. The company expects net proceeds of about $8.75 million, to be used to fund development programs, working capital and other general corporate purposes, with closing anticipated on or about December 19, 2025.
The Pre-Funded Warrants are exercisable at $0.0001 per ADS, while the Series L and related placement agent warrants are exercisable at $3.28 per ADS and expire five years after issuance, subject to 4.99% or 9.99% beneficial ownership limits. As of September 30, 2025, the company reported unaudited cash and cash equivalents of £2.79 million, and after the offering closes, it expects to have 83,878,708,922 ordinary shares outstanding assuming no warrant exercises.
Biodexa Pharmaceuticals PLC is registering up to 5,923,377,900,000 Ordinary Shares in the form of American Depositary Shares to support a best-efforts public offering of up to 3,536,345 Units or Pre-Funded Units. Each Unit includes one Depositary Share (representing 100,000 Ordinary Shares) and one Series L warrant with an initial exercise price set at 225% of the Unit price, plus complex reset and "zero cash exercise price" features that can sharply increase shares issued without bringing in additional cash.
The company estimates net proceeds of about $15.5 million if all Units are sold, to fund its drug development programs, working capital and general corporate purposes. As of December 1, 2025, it had 68,178,708,922 Ordinary Shares outstanding, and if all Ordinary Shares offered were issued they would equal roughly 98.9% of that total, meaning very high potential dilution. Biodexa is a clinical-stage biotech focused on eRapa for familial adenomatous polyposis and non‑muscle invasive bladder cancer, tolimidone for type 1 diabetes, and MTX110 for rare brain cancers, with eRapa already in a Phase 3 FAP trial and supported by a $3.0 million CPRIT grant and FDA fast track status. Cash and cash equivalents were £2.79 million as of September 30, 2025, based on unaudited figures.
Biodexa Pharmaceuticals PLC is registering 109,800,000 Ordinary Shares represented by 1,098 Depositary Shares for resale by holders of Series D warrants issued in a June 2023 private placement. The company is not selling any Depositary Shares in this offering and will not receive proceeds from shareholder resales, although it could receive up to $4.4 million if all Series D Warrants are exercised for cash.
Ordinary Shares outstanding were 61,952,308,922 as of November 1, 2025. Biodexa is a clinical-stage biopharmaceutical company focused on eRapa for familial adenomatous polyposis and non-muscle invasive bladder cancer, and tolimidone for type 1 diabetes, while MTX110 for rare brain cancers has been de-prioritized. eRapa has FDA fast track designation and European orphan drug designation, with an ongoing Phase 3 FAP trial and Phase 2 NMIBC study.
As of September 30, 2025, Biodexa reported unaudited cash and cash equivalents of £2.79 million. The prospectus highlights that large-scale resale of shares could pressure the market price and that future issuances may dilute existing holders.
Biodexa Pharmaceuticals (BDRX) has filed a resale registration covering 171,700,000 Ordinary Shares represented by 1,717 American Depositary Shares, issuable upon exercise of pre-funded warrants from a December 2023 private placement. All sale proceeds for these shares will go to the selling shareholders; Biodexa would receive only any cash exercise proceeds at an exercise price of $0.025 per share.
Ordinary Shares outstanding were 61,952,308,922 as of November 1, 2025. Biodexa is a clinical-stage biopharmaceutical company focused on eRapa for familial adenomatous polyposis and non-muscle invasive bladder cancer, and tolimidone for type 1 diabetes, with MTX110 for rare brain cancers de-prioritized due to resource constraints.
eRapa has fast track designation from the U.S. FDA and orphan drug designation in Europe for FAP, with a Phase 3 study underway and supported by a $3.0 million CPRIT grant. As of September 30, 2025, cash and cash equivalents were £2.79 million, highlighting the importance of external funding sources for ongoing development. The company does not expect to pay dividends in the foreseeable future.